News | News By Subject | News by Disease News By Date | Search News

Multiple myeloma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
bluebird bio (BLUE), Celgene (CELG)'s Multiple Myeloma CAR-T Drug Shines in Tiny Study     12/2/2016
The History Between a Biogen (BIIB) Drug and a High-Profile Democratic Party Fundraiser     10/17/2016
Karyopharm (KPTI) Touts Mid-Stage Data, May See Quicker Approval of Multiple Myeloma Drug     9/6/2016
3 Biotechs Expecting to Release Clinical Trial Data Soon     9/1/2016
Genmab, Inc. (GEN.CO), Johnson & Johnson (JNJ)'s Daratumumab Granted Breakthrough Tag by the FDA     7/26/2016
Amgen (AMGN) Flinches Over Meeting to Review Cost of Multiple Myeloma Drugs     4/7/2016
Janssen Research & Development, Genentech (RHHBY) Forge Clinical Trials Agreement     3/23/2016
Three Drugs Could Catapult Three Big Pharma Revenues This Year     2/9/2016
FDA Grants Full Approval for Amgen (AMGN)'s Blood Cancer Drug     1/25/2016
FDA Approves Takeda (TKPYY)'s Ixazomib for Multiple Myeloma     11/20/2015
Johnson & Johnson (JNJ) Snags Early Approval for Breakthrough Multiple Myeloma Drug Darzalex     11/17/2015
FDA Declines to Approve Spectrum Pharma (SPPI)'s Evomela for Injection     10/23/2015
Three Cancer Drugs are Up for FDA Approval in October     9/28/2015
Karyopharm (KPTI) Tanks After Cancer Drug Trial Patients Get Sepsis     8/10/2015
Exciting Time for Biotech in New Jersey     6/29/2015

News from Around the Web
Amgen (AMGN)’s Backup Plan For Kyprolis Flop     9/30/2016
American Society of Hematology: Secondary Cancers Cloud Myeloma Drug, Roswell Park Cancer Institute Study     12/10/2010
High Response Rates Seen In Phase-III Trial Of Chemotherapy, New Drug And Stem Cells In Myeloma, Azienda Ospedaliera Universitaria San Giovanni Battista of Torino Study     10/14/2010
Possible Genetic Links Between Environmental Toxins And Multiple Myeloma, Bank on a Cure(R) Study     8/14/2009
Treatment With Anti-anemia Drugs May Not Be Safe For Multiple Myeloma Patients, American Journal of Hematology     8/15/2008
One Gene May Be Key to Myeloma, National Cancer Institute Researchers Find     6/24/2008
Blocking a Single Protein Proves Toxic to Myeloma Cells in National Institutes of Health (NIH) Studies     6/23/2008
Three-Drug Combination "Extremely Promising" As First-Line Therapy for Multiple Myeloma, Researchers Say     12/14/2007
New Therapeutic Options for Newly Diagnosed Multiple Myeloma Patients     12/11/2007
Mayo Clinic: Multiple Myeloma Clinical Trial Shows Distinct Survival Benefit with Lower Dose of Steroids     12/10/2007
ZOLINZA (vorinostat) in Combination with Bortezomib Demonstrated Clinical Activity     12/10/2007
Gene Profiling Can Single Out the Worst Cases of Multiple Myeloma and Guide Therapy     9/19/2007
Emory University Researchers Identify Signaling Protein for Multiple Myeloma     9/11/2007
Potential Therapeutic Targets Identified in Multiple Myeloma     8/14/2007
Mayo Clinic Cancer Center Researcher Finds Mold By-product Kills Multiple Myeloma     4/16/2007

Press Releases
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present Initial Results From REO 019 Study In Multiple Myeloma Combining REOLYSIN, Bortezomib And Dexamethasone At The American Society of Hematology Annual Meeting     12/6/2016
Cellectar Biosciences  (CLRB) Presents Poster At The 58th Annual Meeting Of The American Society of Hematology     12/6/2016
Sutro Biopharma ADC Targeting CD74 Exhibits Potent Anti-Tumor Activity In Multiple Malignant Cell Lines And Animal Models Of Non-Hodgkin Lymphoma And Multiple Myeloma     12/6/2016
Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Showed Consistent Clinical Benefit For Previously-Treated Patients With Multiple Myeloma     12/6/2016
Discoveries By GNS Healthcare Causal Machine Learning And Simulation Platform, REFS, Reveal Mechanisms Driving Key Clinical Outcomes In Multiple Myeloma     12/6/2016
Groundbreaking Multiple Myeloma Research Foundation (MMRF) CoMMpass Study(SM) Affirmed As Premier Genomics Data Set In Multiple Myeloma     12/5/2016
Karyopharm (KPTI) Presents Updated Phase IIb STORM Data At The American Society of Hematology 2016 Annual Meeting     12/5/2016
Acetylon Presents Early Phase 1a/1b Results For Citarinostat (ACY-241) In Combination With Pomalyst And Dexamethasone Showing Promising Treatment Responses In Relapsed Or Relapsed-And-Refractory Multiple Myeloma     12/5/2016
Sanofi Genzyme (SNY) Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma     12/5/2016
Autolus Announces First Data Presentation For An APRIL CAR For Multiple Myeloma At The 2016 American Society of Hematology Annual Meeting     12/5/2016
Amgen (AMGN) Announces Launch Of Blood Counts And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma     12/5/2016
Cellectar Biosciences  (CLRB) Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies     12/1/2016
SkylineDx Announces Multiple Studies Being Presented At The 58th Annual American Society of Hematology Meeting Reinforcing Utility Of Mmprofiler Gene-Based Prognostic Signature To Impact Treatment Of Patients With Multiple Myeloma     12/1/2016
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: NINLARO (Ixazomib) Receives Conditional Approval From The European Commission (EC) To Treat Multiple Myeloma     11/28/2016
OncoPep Announces Initiation Of Phase 1b Clinical Trial Of PVX-410 In Smoldering Multiple Myeloma And Upcoming Presentation Of Positive Results From Phase 1/2a Clinical Trial At American Society of Hematology     11/28/2016